FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
RegulatoryapprovedPluvictoPositive
AI Analysis
Summary
Novartis announced FDA approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer, potentially establishing a new standard of care.
Outcome Details
FDA approval for Pluvicto in combination with an androgen receptor pathway inhibitor for metastatic hormone-sensitive prostate cancer
Importance:9/10
Sentiment:
0.95
FDA approvaloncologyprostate cancerPSMA-targeted therapynuclear medicine
Related Companies
Read the original article
Published by GlobeNewswire Pharma on July 31, 2026 8:25 PM